Pasar al contenido principal

ESTUDIO DEL EFECTO DE LA INMUNOTERAPIA Y DEL TRATAMIENTO ANTIRRETROVIRAL A LARGO PLAZO EN LA EVOLUCION DEL RESERVORIO DEL VIH HACIA UNA CURA FUNCIONAL

PID2022-141317OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario INSTITUTO DE SALUD CARLOS III DE MADRID (ISCIII)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Differences in the peripheral blood immune landscape between early-onset and late-onset colorectal cancer

  • Sánchez-Menéndez, Clara
  • Rodríguez-Pérez, Jaime
  • Fuertes, Daniel
  • Leguizamon, Valentina
  • González-Sanmartín, María
  • Mateos, Elena
  • Cervero Jiménez, Miguel|||0000-0001-9387-7917
  • San José, Esther
  • Sanz, Gonzalo
  • Álvaro, Edurne
  • Ballestero-Pérez, Araceli
  • Marti-Gallostra, Marc|||0000-0002-0783-6359
  • Rueda, José Antonio
  • Hurtado-Caballero, Elena
  • Pastor, Carlos
  • Balaguer, Francesc|||0000-0002-0206-0539
  • Spinelli, Antonino
  • Martínez-Laso, Jorge
  • Torres Tarrés, Montserrat
  • Perea, José
  • Coiras, Mayte
Colorectal cancer (CRC) is a leading cause of cancer-related mortality. While screening has reduced incidence in older adults, cases of early-onset CRC (EOCRC), diagnosed before age 50, are rising, highlighting the need to understand its unique biology. Immune responses, particularly T-cell infiltration measured by the tumor-based Immunoscore, are known predictors of CRC prognosis, but less is known about systemic immune differences by age at diagnosis. Peripheral blood mononuclear cells (PBMCs) from EOCRC (n=19) and late-onset CRC (LOCRC; n=19) participants recruited in Madrid (Spain) were analyzed for immune cell phenotypes, exhaustion markers, soluble cytokines, and metabolic activity. Our study revealed distinct peripheral blood immune profiles differentiating EOCRC from LOCRC. EOCRC patients exhibited a heightened proinflammatory environment, with increased functional capacity of CD4+ Th1, Th9, and Th17 subsets to produce IFNg, IL-9, and IL-17A, respectively, and increased plasma levels of IFNg and CXCL8/IL-8. This suggests an active but potentially ineffective immune response. Conversely, LOCRC patients showed hallmarks of immunosenescence and chronic inflammation, including impaired cytokine production, higher frequencies of CD8+ Tgd and Th22 cells, and increased plasma CCL13/MCP-4, consistent with tissue remodeling and immune suppression. Biomarkers distinguishing EOCRC included reduced Th22 and CD8+ Tgd cell frequencies and higher NKT-like cells with increased IL-13 production by Th22 cells. EOCRC and LOCRC involved different immune mechanisms, where EOCRC showed an altered proinflammatory environment with preserved regulatory pathways, while LOCRC reflected age-related immune decline and inflammaging. Peripheral blood immune profiling offers a minimally invasive liquid Immunoscore for early detection and enables personalized immunotherapies for age-related immune landscapes, particularly benefiting younger individuals at risk of EOCRC.
Repisalud
Publicación Artículo científico (JournalArticle)

Differences in the peripheral blood immune landscape between early-onset and late-onset colorectal cancer

  • Sánchez-Menéndez, Clara
  • Rodríguez-Pérez, Jaime
  • Fuertes, Daniel
  • Leguizamon, Valentina
  • González-Sanmartín, María
  • Mateos, Elena
  • Cervero, Miguel
  • San José, Esther
  • Sanz, Gonzalo
  • Álvaro, Edurne
  • Ballestero-Pérez, Araceli
  • Martí-Gallostra, Marc
  • Rueda, José Antonio
  • Hurtado-Caballero, Elena
  • Pastor, Carlos
  • Balaguer, Francesc
  • Spinelli, Antonino
  • Martinez-Laso, Jorge
  • Torres, Montserrat
  • Perea, José
  • Coiras, Mayte
  • Spanish EOCRC Consortium (SECOC)
Introduction: Colorectal cancer (CRC) is a leading cause of cancer-related mortality. While screening has reduced incidence in older adults, cases of early-onset CRC (EOCRC), diagnosed before age 50, are rising, highlighting the need to understand its unique biology. Immune responses, particularly T-cell infiltration measured by the tumor-based Immunoscore, are known predictors of CRC prognosis, but less is known about systemic immune differences by age at diagnosis. Methods: Peripheral blood mononuclear cells (PBMCs) from EOCRC (n=19) and late-onset CRC (LOCRC; n=19) participants recruited in Madrid (Spain) were analyzed for immune cell phenotypes, exhaustion markers, soluble cytokines, and metabolic activity. Results: Our study revealed distinct peripheral blood immune profiles differentiating EOCRC from LOCRC. EOCRC patients exhibited a heightened proinflammatory environment, with increased functional capacity of CD4+ Th1, Th9, and Th17 subsets to produce IFNg, IL-9, and IL-17A, respectively, and increased plasma levels of IFNg and CXCL8/IL-8. This suggests an active but potentially ineffective immune response. Conversely, LOCRC patients showed hallmarks of immunosenescence and chronic inflammation, including impaired cytokine production, higher frequencies of CD8+ Tgd and Th22 cells, and increased plasma CCL13/MCP-4, consistent with tissue remodeling and immune suppression. Biomarkers distinguishing EOCRC included reduced Th22 and CD8+ Tgd cell frequencies and higher NKT-like cells with increased IL-13 production by Th22 cells. Conclusions: EOCRC and LOCRC involved different immune mechanisms, where EOCRC showed an altered proinflammatory environment with preserved regulatory pathways, while LOCRC reflected age-related immune decline and inflammaging. Peripheral blood immune profiling offers a minimally invasive liquid Immunoscore for early detection and enables personalized immunotherapies for age-related immune landscapes, particularly benefiting younger individuals at risk of EOCRC.
Repisalud
Publicación Artículo científico (JournalArticle)

Sustained antiviral response against HIV-1 infection in peripheral blood mononuclear cells from people with chronic myeloid leukemia treated with ponatinib.

  • Manzanares, Mario
  • Ramos-Martín, Fernando
  • Rodriguez Mora, Sara
  • Casado-Fernández, Guiomar
  • Sánchez-Menéndez, Clara
  • Simón-Rueda, Alicia
  • Mateos, Elena
  • Cervero, Miguel
  • Spivak, Adam M
  • Planelles, Vicente
  • Torres, Montserrat
  • García-Gutiérrez, Valentín
  • Coiras, Mayte
HIV-1 infection cannot be cured due to long-lived viral reservoirs formed by latently infected CD4 T cells. "Shock and Kill" strategy has been considered to eliminate the viral reservoir and achieve a functional cure but the stimulation of cytotoxic immunity is necessary. Ponatinib is a tyrosine kinase inhibitor (TKI) clinically used against chronic myeloid leukemia (CML) that has demonstrated to be effective against HIV-1 infection . Several TKIs may induce a potent cytotoxic response against cancer cells that makes possible to discontinue treatment in people with CML who present long-term deep molecular response. In this longitudinal study, we analyzed the capacity of ponatinib to induce an antiviral response against HIV-1 infection in peripheral blood mononuclear cells (PBMCs) obtained from people with CML previously treated with imatinib for a median of 10 years who changed to ponatinib for 12 months to boost the anticancer response before discontinuing any TKI as part of the clinical trial NCT04043676. Participants were followed-up for an additional 12 months in the absence of treatment. PBMCs were obtained at different time points and then infected with HIV-1. The rate of infection was determined by quantifying the intracellular levels of p24-gag in CD4 T cells. The levels of p24-gag+ CD4 T-cells were lower when these cells were obtained during and after treatment with ponatinib in comparison with those obtained during treatment with imatinib. Cytotoxicity of PBMCs against HIV-infected target cells was significantly higher during treatment with ponatinib than during treatment with imatinib, and it was maintained at least 12 months after discontinuation. There was a significant negative correlation between the lower levels of p24-gag+ CD4 T-cells and the higher cytotoxicity induced by PBMCs when cells were obtained during and after treatment with ponatinib. This cytotoxic immunity was mostly based on higher levels of Natural Killer and Tγδ cells seemingly boosted by ponatinib. In conclusion, transient treatment with immunomodulators like ponatinib along with ART could be explored to boost the antiviral activity of cytotoxic cells and contribute to the elimination of HIV-1 reservoir.
Repisalud
Publicación Artículo científico (JournalArticle)

Low Specific T-Cell Immunity Against Mpox Elicited in People With HIV-1 and PrEP Users After Subcutaneous Vaccination Compared to Natural Infection.

  • Calle-Jiménez, Olivia de la
  • Casado-Fernández, Guiomar
  • Armenteros-Yeguas, Inés
  • Lemus-Aguilar, Luis
  • Baza, Begoña
  • Pérez-García, Jorge Alfredo
  • Rodríguez-Añover, Javier
  • Mateos, Elena
  • Homen, Reynaldo
  • Orviz-García, Eva
  • Cabello, Noemí
  • Negredo, Anabel
  • Sánchez-Seco, María Paz
  • Del Romero, Jorge
  • Estrada, Vicente
  • Torres, Montserrat
  • Coiras, Mayte
In August 2024, the World Health Organization declared mpox infection a Public Health Emergency of International Concern for second time since 2022 and recommended vaccinating all people at-risk, such as people with HIV-1 (PWH) and prophylaxis pre-exposition (PrEP) users. We recruited PWH and PrEP users who received one or two doses of subcutaneous Imvanex® or Jynneos® and compared specific T-cell immunity with participants who passed mpox natural infection or were Nonexposed to mpox. CD4 + T cells from people who had mpox showed the highest capacity to produce IL-2 (1.8-fold, p = 0.0328), as well as IFNγ (2.5-fold, p = 0.0247), and IL-4 (1.8-fold, p = 0.0373) from naïve CD4 + T cells, in response to MHC-II-restricted mpox-related peptides, compared to vaccinated participants. CD8 + T cells from individuals who had mpox also showed the highest capacity to produce IFN (1.6-fold, p = 0.0321) and TNF (2.1-fold, p = 0.0084) against MHC-I-restricted peptides. Therefore, the most potent and robust T-cell responses were developed after mpox infection, while they were barely detectable after vaccination. These results support the need to explore booster doses or improved vaccines to enhance cellular immunity in at-risk populations. More studies are needed to evaluate the capacity of mpox vaccines to confer long-term protection.
Repisalud
Publicación Artículo científico (JournalArticle)

Novel alternative transcripts of TLR8 and TLR9 reveal evolutionary pressure to conserve protein structure.

  • Martinez-Laso, Jorge
  • Cervera Hernandez, Isabel
  • Muñoz-Gómez, María José
  • Sánchez-Menéndez, Clara
  • Torres, Montserrat
  • Salamanca-Soto, Ana
  • Torres, Montserrat
  • Coiras, Mayte
TLR8 and TLR9 are innate immune receptors belonging to the TLR family that are essential for viral recognition and early immune activation. Their dysfunction is linked to increased susceptibility to infections. TLR8 detects viral single- and double-stranded RNA, while TLR9 recognizes viral DNA molecules with CpG motifs. Six TLR8 alternative transcripts (V1, V2, V5, V6, V7, and V8) and nine TLR9 (V1, A, B, C, D, E, V8, V9, and V10) have been previously described in humans. In the present study, we have performed a comprehensive analysis of TLR8 and TLR9 transcripts in a healthy population and two new TLR8 transcripts (V3 and V4) and four new TLR9 transcripts (V2, V5, V6, and V7) were found. The main mechanisms for the generation of different mRNA variants were the insertion of non-coding regions and the loss of whole or partial exons. These changes result in the loss or insertion of new amino acids but only modify the initial leucine-rich repeat (LRR) region and preserve the rest of the receptor's complete structure. From the results obtained, we can deduce that there seems to be a strong evolutionary drive to maintain TLR8 and TLR9 functionality, unlike other innate immune response receptors.